Screening and Model Systems for Therapies of Alzheimer Disease (AD)
A new strategy for the therapy of AD describes that moderate enhancement of the α-secretase ADAM10 completely inhibits amyloid plaque deposition and enhances the production of the N-terminal domain of the amyloid precursor protein (APP), that acts as neuropotective component. As a consequence, these effects improve synaptic plasticity and reduces cognitive defects shown in a transgenic mouse model for AD.
Further Information: PDF
IMG Innovations-Management GmbH
Phone: +49 (0)631/31668-0
Contact
Dr. Klaus Kobek
Media Contact
All latest news from the category: Technology Offerings
Newest articles
You are What You Eat—Stanford Study Links Fiber to Anti-Cancer Gene Modulation
The Fiber Gap: A Growing Concern in American Diets Fiber is well known to be an important part of a healthy diet, yet less than 10% of Americans eat the minimum recommended…
Trust Your Gut—RNA-Protein Discovery for Better Immunity
HIRI researchers uncover control mechanisms of polysaccharide utilization in Bacteroides thetaiotaomicron. Researchers at the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Julius-Maximilians-Universität (JMU) in Würzburg have identified a…
ASXL1 Mutation: The Hidden Trigger Behind Blood Cancers and Inflammation
Scientists show how a mutated gene harms red and white blood cells. LA JOLLA, CA—Scientists at La Jolla Institute for Immunology (LJI) have discovered how a mutated gene kicks off…